● Growth is a substantial asset for the company, as anticipated by dedicated analysts. Within the next three years, growth is estimated to reach 58% by 2028.
● The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
● The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
● Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
● Thanks to a sound financial situation, the firm has significant leeway for investment.
● The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
● Over the past twelve months, analysts' opinions have been strongly revised upwards.
Weaknesses
● Based on current prices, the company has particularly high valuation levels.
● In relation to the value of its tangible assets, the company's valuation appears relatively high.
● For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
● For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
● Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
